. Author manuscript; available in PMC: 2009 Sep 1.

Published in final edited form as: Best Pract Res Clin Haematol. 2008 Sep;21(3):405–420. doi: 10.1016/j.beha.2008.06.002

Table 2.

Adoptive T-cell therapies for Epstein-Barr-virus-positive Hodgkin’s disease and non-Hodgkin’s lymphoma.

Adoptive immunotherapy	Disease type	Patients, n	Results	References
Allogeneic EBV-specific CTLs
Allogeneic EBV-CTLs	EBV-HD and NHL	4	1 CR, 1 CRU, 1 PR, 1 NR	Sun et al (71)
Allogeneic EBV-CTLs pretreated with fludarabine	Relapsed EBV-HD	6	1 CR, 4 PR, 1 NR	Lucas et al (38)
Autologous EBV-specific CTLs
Autologous EBV-CTLs	Relapsed EBV-HD	14	5 CR, 1 PR, 5 SD, 3 NR	Roskrow et al (72) and Bollard et al (36)
Autologous EBV-CTLs	Extranodal NK/T-cell lymphoma, nasal type	3	2 SD for over 3 years	Cho et al (37)
Autologous LMP2-specific CTLs
Autologous LMP2-CTLs	Relapsed EBV-HD and NHL	6	4 CR, 1 PR, 1 NR	Bollard et al (44)
Autologous LMP2-CTLs	EBV-HD and NHL – adjuvant therapy after auto SCT or chemo	10	9 CR, 1 NR	Bollard et al (44)

CR, complete response; CRU, clinical response undetermined; PR, partial response; NR, no response; HD, Hodgkin’s disease; NHL, non-Hodgkin’s lymphoma; EBV, Epstein-Barr virus; CTL, cytotoxic T lymphocyte; NK, natural killer.